Robert A. Hegele

Active 1986–2026

Also published as
Robert A Hegele
326
Papers
54,670
Citations
118
h-index
312
i10-index

Citations

Citations per year for Robert A. Hegele1985: 3 citations1987: 2 citations1988: 8 citations1989: 13 citations1990: 15 citations1991: 23 citations1992: 17 citations1993: 12 citations1994: 20 citations1995: 21 citations1996: 25 citations1997: 44 citations1998: 46 citations1999: 47 citations2000: 62 citations2001: 74 citations2002: 73 citations2003: 102 citations2004: 109 citations2005: 96 citations2006: 110 citations2007: 113 citations2008: 116 citations2009: 136 citations2010: 197 citations2011: 251 citations2012: 204 citations2013: 258 citations2014: 313 citations2015: 400 citations2016: 488 citations2017: 434 citations2018: 467 citations2019: 1,601 citations2020: 1,842 citations2021: 1,814 citations2022: 1,624 citations2023: 1,303 citations2024: 2,329 citations2025: 1,251 citations2026: 94 citations1986: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,938 citing papers, 19.8% of this breakdownCanada: 1,627 citing papers, 8.2% of this breakdownChina: 1,489 citing papers, 7.5% of this breakdownUnited Kingdom: 1,450 citing papers, 7.3% of this breakdownItaly: 954 citing papers, 4.8% of this breakdownGermany: 781 citing papers, 3.9% of this breakdownAustralia: 716 citing papers, 3.6% of this breakdownNetherlands: 706 citing papers, 3.5% of this breakdownSpain: 597 citing papers, 3% of this breakdownFrance: 576 citing papers, 2.9% of this breakdownJapan: 409 citing papers, 2.1% of this breakdownSweden: 364 citing papers, 1.8% of this breakdown
0%19.8%Other 31.6%

Fields

  • Medicine67%
  • Biochemistry, Genetics and Molecular Biology21.9%
  • Immunology and Microbiology2.2%
  • Nursing2.2%
  • Neuroscience1.3%
  • Health Professions0.8%
  • Other4.6%

Topics

  • Lipoproteins and Cardiovascular Health10.7%
  • Diabetes, Cardiovascular Risks, and Lipoproteins7.4%
  • Lipid metabolism and disorders3.1%
  • Cholesterol and Lipid Metabolism2.5%
  • Cancer, Lipids, and Metabolism2.5%
  • Atherosclerosis and Cardiovascular Diseases2.1%
  • Other71.7%

Coauthors

All papers

Open in search
  1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2017 cited by 3,840

  2. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2020 cited by 1,527

  3. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2021 cited by 899

  4. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Canadian Journal of Cardiology 2021 cited by 833

  5. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

    Authors: , , , , , , , , , , , , , , , , , , , , , - Canadian Journal of Cardiology 2016 cited by 1,179

  6. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2013 cited by 2,737

  7. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

    Authors: , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2023 cited by 331

  8. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan A. Stein, Lâle Tokgözoğlu, Børge G. Nordestgaard, Eric Bruckert, Ronald M. Krauss, Ulrich Laufs, Raul D. Santos, Winfried März, Connie B. Newman, M. John Chapman, Henry N. Ginsberg, M. John Chapman, Henry N. Ginsberg, Guy De Backer, Alberico L. Catapano, Robert A. Hegele, G. Kees Hovingh, Terry A. Jacobson, Lawrence A. Leiter, François Mach, Olov Wiklund - European Heart Journal 2015 cited by 1,420

  9. A Modern Approach to Dyslipidemia

    Authors: , - Endocrine Reviews 2021 cited by 449

  10. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 237

  11. Clinical review on triglycerides

    Authors: , , , - European Heart Journal 2019 cited by 542

  12. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 195

  13. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Cardiology 2023 cited by 226

  14. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jesse Bittman, Peter Bolli, Anne‐Marie Côté, Janis M. Dionne, Andrew Don-Wauchope, Cedric Edwards, Tabassum Firoz, Jonathan Y. Gabor, Richard E. Gilbert, Jean‐Claude Grégoire, Steven E. Gryn, Milan Gupta, Fady Hannah‐Shmouni, Robert A. Hegele, Robert J. Herman, Michael D. Hill, Jonathan G. Howlett, Gregory L. Hundemer, Charlotte Jones, Janusz Kaczorowski, Nadia Khan, Laura M. Kuyper, Maxime Lamarre-Cliché, Kim Lavoie, Lawrence A. Leiter, Richard Lewanczuk, Alexander G. Logan, Laura A. Magee, Birinder Mangat, Philip A. McFarlane, Donna McLean, André Michaud, Alain Milot, Gordon W. Moe, S. Brian Penner, Andrew Pipe, Alexandre Y. Poppe, Évelyne Rey, Michael Roerecke, Ernesto L. Schiffrin, Peter Selby, Mike Sharma, Ashkan Shoamanesh, Praveena Sivapalan, Raymond R. Townsend, Karen C. Tran, Luc Trudeau, Ross T. Tsuyuki, Michel Vallée, Vincent Woo, Alan Bell, Stella S. Daskalopoulou - Canadian Journal of Cardiology 2020 cited by 587

  15. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ulrich Julius, John P. Kane, Michel Krempf, Steven W. Martin, James J. Powell, Richard Shultzaberger, Craig Thompson, Letitia Thompson-Hargrave, Peter P. Tóth, Traci Turner, René Valéro, Bruno Vergès, Frank L.J. Visseren, Pankaj Vyas, Alberto R. Yataco - The Lancet Diabetes & Endocrinology 2021 cited by 226

  16. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pascale Richard, Flavie Ader, Eric Villard, Peter Lichtner, Thomas Meitinger, Michael W.T. Tanck, J. Peter van Tintelen, Andrew Thain, David McCarty, Robert A. Hegele, Jason D. Roberts, Julie Amyot, Marie‐Pierre Dubé, Julia Cadrin‐Tourigny, Geneviève Giraldeau, Philippe L. L’Allier, Patrick Garceau, Jean‐Claude Tardif, S. Matthijs Boekholdt, R Thomas Lumbers, Folkert W. Asselbergs, Paul J.R. Barton, Stuart A. Cook, Sanjay Prasad, Declan P. O’Regan, Jolanda van der Velden, Karin J. H. Verweij, Mario Talajic, Guillaume Lettre, Yigal M. Pinto, Benjamin Meder, Philippe Charron, Rudolf A. de Boer, Imke Christiaans, Michelle Michels, Arthur A.M. Wilde, Hugh Watkins, Paul M. Matthews, James S. Ware, Connie R. Bezzina - Nature Genetics 2021 cited by 292

  17. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

    Authors: , , , , , , , , , , , , , , , , , - Nature Medicine 2023 cited by 95

  18. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daisy Rymen, Peter Witters, Raúl D. Santos, Liam R. Brunham, Gordon A. Francis, Jacques Genest, Robert A. Hegele, Brooke A. Kennedy, Isabelle L. Ruel, Mark Sherman, Long Jiang, Luya Wang, Željko Reiner, V. Bláha, R Češka, Jana Dvořáková, Lubomir Dlouhy, Pavel Hořák, Vladimír Soška, Lukáš Tichý, Robin Urbánek, H Vaverková, Michal Vrablı́k, Stanislav Zemek, Lukáš Zlatohlávek, Sameh Emil, Tarek Naguib, Ashraf Reda, Sophie Béliard, Éric Bruckert, Antonio Gallo, Moses Elisaf, Genovefa Kolovou, Hofit Cohen, Ronen Durst, Eldad J. Dann, Avishay Elis, Osama Hussein, Eran Leitersdorf, Daniel Schurr, Nitika Setia, Ishwar C. Verma, Mohammed Alareedh, Mutaz Al-Khnifsawi, Ali Fawzi Abdalsahib Al-Zamili, Sabah H. Rhadi, Foaad Shaghee, Marcello Arca, Maurizio Averna, Andrea Bartuli, Marco Bucci, Paola Sabrina Buonuomo, Paolo Calabrò, S. Calandra, Manuela Casula, Alberico L. Catapano, Angelo B. Cefalù, Arrigo F.G. Cicero, Sergio D’Addato, Laura D’Erasmo, Alessia Di Costanzo, Tommaso Fasano, Marta Gazzotti, Antonina Giammanco, Gabriella Iannuzzo, Anastasia Ibba, Emanuele Alberto Negri, Andrea Pasta, Chiara Pavanello, Livia Pisciotta and 73 more - The Lancet 2022 cited by 207

  19. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 152

  20. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , - The Lancet 2012 cited by 740

  21. The Evolving Future of PCSK9 Inhibitors

    Authors: , , , - Journal of the American College of Cardiology 2018 cited by 264

  22. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anne Tybjærg‐Hansen, Olov Wiklund - European Heart Journal 2015 cited by 870

  23. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2018 cited by 381

  24. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , for the European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia, M. Cuchel, Éric Bruckert, M. John Chapman, O. S. Descamps, H. N. Ginsberg, Robert A. Hegele, Jan Albert Kuivenhoven, B. G. Nordestgaard, F. J. Raal, R. D. Santos, E. Steinhagen-Thiessen, Anne Tybjærg‐Hansen, Gerald F. Watts, M. John Chapman, Henry N. Ginsberg, Maurizio Averna, Cathérine Boileau, J. Boren, Alberico L. Catapano, Joep C. Defesche, G. K. Hovingh, Steve E. Humphries, Petri T. Kovanen, L. Masana, P. Pajukanta, Klaus G. Parhofer, Kausik K. Ray, Anton F. H. Stalenhoef, Erik S.G. Stroes, Marja‐Riitta Taskinen, Albert Wiegman, Olov Wiklund - European Heart Journal 2014 cited by 1,053